Finnhub•2026-04-21
Viemed Healthcare Announces First Quarter 2026 Earnings Conference Call DetailsVMD — Viemed Healthcare Inc
NASDAQ · Health Care · Health Care
$9.26+27.02%Market cap355.14M
- Latest Close
- $9.26
- 30-Day Move
- +27.0%
- Market Cap
- $355M
- Shares Outstanding
- 38,600,000
- P/E Ratio
- 24.78
- P/B Ratio
- 2
Analyst consensus: Buy · 6 analysts
NASDAQ:VMDHealth Care / Health CareDelayed public snapshot
Viemed Healthcare Inc
A read-only Alphactor snapshot forViemed Healthcare Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$9.26
30-Day Move
+27.0%
Market Cap
$355M
Shares Outstanding
38,600,000
P/E Ratio
24.78
P/B Ratio
2
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$9.26
+27.0%last 90 delayed daily bars
Market cap$355M
90D High
$10.06
90D Low
$7.11
Avg Volume
233,724
What stands out
Gross margin is running at 57.5%, which gives a quick read on operating quality before you open the full model.
Net margin is 5.5%, useful for comparing VMD against peers in Health Care.
VMD is up 27.0% over the last 30 trading days shown on this page.
Latest operating income is $9M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$15.93
Rule of 40
24.9%
Dark Pool Short %
27.9%
Fundamentals snapshot
Latest Close
$9.26
30-Day Move
+27.0%
Market Cap
$355M
Shares Outstanding
38,600,000
P/E Ratio
24.78
P/B Ratio
2
ROE
10.5%
ROA
7.5%
Gross Margin
57.5%
Operating Margin
8.5%
Net Margin
5.5%
Debt / Equity
0.09
Current Ratio
1.18
Latest Revenue
$76M
Financial statement snapshot
Revenue
$76M
Gross Profit
$44M
Operating Income
$9M
Net Income
$6M
Gross Margin
5752.0%
Net Margin
553.0%
Current Ratio
1.18
Debt / Equity
0.09
Valuation snapshot
Fair Value
$15.93
Upside / Downside
+72.0%
Signal
Undervalued
Implied Growth
14.8%
DCF
$9.05
EPV
$3.78
EV/Rev
$34.95
Growth Assumption
24.9%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$12M
Valuation spread
Current Price
$9.26
Composite Fair Value
$15.93
DCF
$9.05
EPV
$3.78
EV/Rev
$34.95
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
6.30
Safe
Piotroski
5
Moderate (4-6)
Cash Conversion
3.48x
Rule of 40
24.9%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $139M | $9M | $6M | $5M |
| 2023-12-31 | $183M | $15M | $10M | $19M |
| 2024-12-31 | $224M | $16M | $11M | $1M |
| 2025-12-31 | $270M | $21M | $15M | $12M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
ChartMill•2026-04-17
Viemed Healthcare Inc (NASDAQ:VMD) Identified as a CAN SLIM Growth CandidateAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Insider activity snapshot
Buy Value
$0
Sell Value
$1M
Buys
0
Sells
3
Buy Value
$0
Sell Value
$1M
Buy/Sell Ratio
0.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-20 | Moore Michael | Sell | 65,000 | $8.77 |
| 2026-03-19 | Moore Michael | Sell | 40,232 | $9.21 |
| 2026-03-18 | Moore Michael | Sell | 31,570 | $9.42 |
| 2026-01-29 | Trahan Jeremy | M | 3,591 | $0.00 |
| 2026-01-29 | Trahan Jeremy | M | 10,774 | $0.00 |
| 2026-01-29 | Trahan Jeremy | D | 3,591 | $7.48 |
| 2026-01-29 | Trahan Jeremy | M | 3,591 | $0.00 |
| 2026-01-29 | Trahan Jeremy | F | 2,939 | $7.48 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 909,918 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 798,778 | 0.02% | 2026-02-28 |
| Columbia Funds Series Trust I-Columbia Small Cap Value Discovery Fund | 513,130 | 0.01% | 2026-01-31 |
| BlackRock Funds-BlackRock Advantage Small Cap Core Fund | 503,621 | 0.01% | 2025-11-30 |
| First Eagle Funds-First Eagle Small Cap Opportunity Fund | 462,272 | 0.01% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 365,256 | 0.01% | 2025-12-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 329,355 | 0.01% | 2026-01-31 |
| iShares Trust-iShares Russell 2000 Growth ETF | 287,337 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$24M
--
Vanguard Group
Filed 2026-01-29
$13M
-1.2%
Goldman Sachs
Filed 2026-02-10
$11M
+3.6%
Geode Capital Management
Filed 2026-02-09
$6M
-2.7%
Renaissance Technologies
Filed 2026-02-12
$3M
-1.4%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
6
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.